Elsius is a Canadian company based in Calgary that will produce and commercialize worldwide an innovative ECMO system. It will address the shortcomings of current clinical systems in terms of not optimal patient recovery and cost containment. Our technology will ultimately lead to a higher number of saved lives, shorter hospitalization times and lower costs to healthcare systems everywhere.
ECMO was invented by Dr. Bartlett in Ann Harbor Michigan, in the 60s and 70s to treat premature babies with lungs development issues. ECMO has remained confined to the pediatric realm, seeing very little innovation, till the mid 2000, when the first flu pandemics of the modern era happened.
ECMO is a very complex lifesaving technology that provides circulatory and respiratory support to very sick patients experiencing some kind of circulatory or respiratory failures.
EBS (Ension Bioactive Surface)
EBS is part of a set of solutions to enhance the biocompatibility of ECMO and the results so far have been so good that not only it could make the usage of ECMO mainstream but it could transform the way we look at blood contacting surfaces altogether.
Elsius: invest rationally
How often is one confronted with the opportunity to invest in an emerging technology that could truly benefit a part of humanity that is sick and in need of help, while at the same time profiting from this endeavor?